[1] 沈山梅,朱大龙,黄洪,等.新诊断格雷夫斯病患者肝功能变化与甲状腺激素及抗体的关系.中国实用内科杂志,2005:733-734. [2] Elias RM,Dean DS,Barsness GW.Hepatic dysfunction in hospitalized patients with acute thyrotoxicosis:a decade of experience.ISRN Endocrinol,2012,2012:325092. [3] 吴作艳,王炳元.甲亢性肝损害.中国实用内科杂志,2002:311-312. [4] 田竹芳,施秉银,赵新,等.Graves病患者甲亢性肝损害及其相关因素分析.西安交通大学学报(医学版),2010,31:205-207+230. [5] 肝衰竭诊治指南(2018年版).西南医科大学学报,2019,42:99-106. [6] Weetman AP,Wiersinga WM.Current management of thyroid-associated ophthalmopathy in Europe.Results of an international survey.Clin Endocrinol (Oxf),1998,49:21-28. [7] Ross DS,Burch HB,Cooper DS,et al.2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.Thyroid,2016,26:1343-1421. [8] 景婧,罗生强,宫嫚,等.甲状腺功能亢进症致亚急性肝衰竭1例报告.临床肝胆病杂志,2013,29:707-708. [9] Chou C,Wong RJ,Higgins JP,et al.Acute liver failure:a potential complication of antithyroid medication use.Dig Dis Sci,2015,60:1924-1927. [10] 蒋宁一,林岩松,关海霞,等.(131)I治疗格雷夫斯甲亢指南(2013版).标记免疫分析与临床,2014,21:92-104. [11] 崔京男,姜红丽.毒性弥漫性甲状腺肿的糖皮质激素治疗现状.中国当代医药,2014,21:189-190+193. [12] 马中书,邱明才.糖皮质激素在自身免疫性甲状腺疾病治疗中的选择和应用.中国全科医学,2010,13:113-115. [13] Keklik M,Kaynar L,Yilmaz M,et al.The results of therapeutic plasma exchange in patients with severe hyperthyroidism:a retrospective multicenter study.Transfus Apher Sci,2013,48:327-330. [14] 林学,陈川英,陈芳,等.甲状腺功能亢进合并亚急性肝衰竭不同方法治疗效果的临床分析.中国现代医生,2018,56:85-87. [15] Alfadhli E,Gianoukakis AG.Management of severe thyrotoxicosis when the gastrointestinal tract is compromised.Thyroid,2011,21:215-220. [16] Zhang Q,Guan Y,Xiang T,et al.Combination of molecular adsorbent recirculating system and radioiodine for the treatment of concurrent hyperthyroidism and severe liver dysfunction:a retrospective cohort study.Endocr Pract,2017,23:141-148. |